These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 22279183

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
    Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
    [Abstract] [Full Text] [Related]

  • 3. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
    Baines SD, Saxton K, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
    [Abstract] [Full Text] [Related]

  • 4. Mixed infection by Clostridium difficile in an in vitro model of the human gut.
    Baines SD, Crowther GS, Todhunter SL, Freeman J, Chilton CH, Fawley WN, Wilcox MH.
    J Antimicrob Chemother; 2013 May; 68(5):1139-43. PubMed ID: 23354280
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
    Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
    Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH.
    J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
    Chilton CH, Crowther GS, Todhunter SL, Nicholson S, Freeman J, Chesnel L, Wilcox MH.
    J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
    Chilton CH, Crowther GS, Śpiewak K, Brindell M, Singh G, Wilcox MH, Monaghan TM.
    J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.
    Freeman J, O'Neill FJ, Wilcox MH.
    J Antimicrob Chemother; 2003 Jul; 52(1):96-102. PubMed ID: 12775682
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.
    Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Baines SD, Wilcox MH.
    J Antimicrob Chemother; 2014 Aug; 69(8):2137-47. PubMed ID: 24788662
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.